SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

Payoneer cuts 6% of workforce as profitability pressures mount

Johny Srouji breaks silence: “I don’t plan on leaving Apple anytime soon”

Israeli cybersecurity funding soars to $4.4 billion, up 46% in 2025

“ My main argument for Israeli startups to come to Europe is it's a huge market”

Buzz

Most popular

Daily

Weekly

1

“I can retire… with peace”: Nir Zuk says Palo Alto Networks finally achieved his 20-year vision with $25B CyberArk acquisition

2

Mobileye lays off 200 employees; Company's shares down more than 40% this year

3

Johny Srouji weighs leaving Apple, raising stakes for the Israeli executive who built its silicon program

4

ZIM faces pivotal vote as company weighs at least three acquisition offers

5

Could Prompt Security be SentinelOne’s lifeline as shares slide 35% this year?

Mori Arkin

5 stories about Mori Arkin

Exalenz Bioscience Acquired for $49M

19.02.20|Golan Hazani

Israeli-born billionaire & biomed entrepreneur Mori Arkin sold his company for 6.10 NIS per share. Learn more on CTech!

Biomed Entrepreneur Mori Arkin Nearing Sale of Exalenz to a U.S. Company

19.02.20|Golan Hazani

Tel Aviv-listed Exalenz is not considered one of the serial entrepreneur’s great successes, having lost 73% of its valuation over the past five years. The current deal will see it sold at a premium of tens of percentages, according to one source

סטפן אושמן מנכ"ל Merck

Merck and WuXi AppTec Announce Launch of Biotech Incubator in Israel

20.02.18|Meir Orbach

The incubator program has a five year budget of 20 million euros

Acne Cream Developer Sol-Gel files for $86 Million Nasdaq IPO

31.08.17|Dror Reich

The clinical-stage drug developer will remain a "controlled company" under current shareholder Arkin Dermatology

Anti-Acne Drug Developer Plans Nasdaq IPO

15.08.17|Golan Hazani

Sol-Gel approached potential underwriters. It aims to go public before the end of the year